Drugs / MW05
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT04554056 | Sep 2020 → Aug 2022 | female breast carcinoma | Mabwell (Shanghai) Bioscience Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MW05 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04554056 ↗ |
| Known as | MW05 injection | “MW05 injection” NCT04554056 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant (yeast secreted) human serum albumin-human granulocyte colony stimulating factor (I) fusion protein injection” NCT04554056 ↗ |
| Route | Subcutaneous | “MW05(300 μg/kg s.c.)” NCT04554056 ↗ |